Proteomics

Dataset Information

0

TMT-labeled mass spectrometry-based proteomics analysis in NCI-H1581 lung cancer cells upon AZD4547 treatment


ABSTRACT: FGFR1-amplified lung cancer cell line NCI-H1581 was treated with FGFR inhibitor AZD4547 (0.1μM) or DMSO vehicle for 24 hours. Then TMT-labeled mass spectrometry-based proteomics was carried out in cell lysates to analyze the differentially expressed proteins between two groups.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung, Epithelial Cell Of Lung

DISEASE(S): Non-small Cell Lung Carcinoma

SUBMITTER: Jing Gao  

LAB HEAD: Zhou Hu

PROVIDER: PXD032227 | Pride | 2022-10-13

REPOSITORIES: Pride

altmetric image

Publications

<sup>18</sup>F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis.

Jiang Yuchen Y   Zeng Qinghe Q   Jiang Qinghui Q   Peng Xia X   Gao Jing J   Wan Haiyan H   Wang Luting L   Gao Yinglei Y   Zhou Xiaoyu X   Lin Dongze D   Feng Hanyi H   Liang Sheng S   Zhou Hu H   Ding Jian J   Ai Jing J   Huang Ruimin R  

Theranostics 20220829 14


<b>Rationale:</b> The overall clinical response to FGFR inhibitor (FGFRi) is far from satisfactory in cancer patients stratified by FGFR aberration, the current biomarker in clinical practice. A novel biomarker to evaluate the therapeutic response to FGFRi in a non-invasive and dynamic manner is thus greatly desired. <b>Methods:</b> Six FGFR-aberrant cancer cell lines were used, including four FGFRi-sensitive ones (NCI-H1581, NCI-H716, RT112 and Hep3B) and two FGFRi-resistant ones (primary for N  ...[more]

Similar Datasets

2019-09-27 | PXD015182 | Pride
2018-05-07 | PXD007726 | Pride
2020-11-19 | PXD022130 | Pride
2009-12-19 | E-GEOD-13902 | biostudies-arrayexpress
2013-06-12 | E-MTAB-1456 | biostudies-arrayexpress
2019-01-24 | PXD011722 | Pride
2020-05-27 | PXD016625 | Pride
2011-03-23 | E-GEOD-28131 | biostudies-arrayexpress
2009-04-29 | E-GEOD-5073 | biostudies-arrayexpress
2022-09-12 | PXD035835 | Pride